BioTelemetry Inc. (NASDAQ:BEAT) reached a new 52-week high during trading on Wednesday . The stock traded as high as $18.70 and last traded at $18.50, with a volume of 398,205 shares trading hands. The stock had previously closed at $17.67.

Separately, Zacks Investment Research lowered BioTelemetry from a “hold” rating to a “sell” rating in a research report on Tuesday, April 19th.

The firm has a market cap of $504.88 million and a PE ratio of 45.82. The firm has a 50-day moving average of $16.60 and a 200-day moving average of $13.41.

BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, April 26th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.10. The business had revenue of $48.60 million for the quarter, compared to the consensus estimate of $46.54 million. During the same quarter in the previous year, the company earned $0.06 earnings per share. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. Equities research analysts predict that BioTelemetry Inc. will post $0.71 EPS for the current year.

A number of large investors have added to or reduced their stakes in the company. 1492 Capital Management LLC boosted its stake in BioTelemetry by 11.4% in the fourth quarter. 1492 Capital Management LLC now owns 321,761 shares of the company’s stock valued at $3,758,000 after buying an additional 32,932 shares during the last quarter. Russell Frank Co increased its position in shares of BioTelemetry by 58.9% in the fourth quarter. Russell Frank Co now owns 249,457 shares of the company’s stock valued at $2,933,000 after buying an additional 92,455 shares during the period. Dimensional Fund Advisors LP increased its position in shares of BioTelemetry by 8.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,317,266 shares of the company’s stock valued at $15,386,000 after buying an additional 98,737 shares during the period. Gabelli Funds LLC bought a new position in shares of BioTelemetry during the fourth quarter valued at about $1,190,000. Finally, Wells Fargo & Company MN increased its position in shares of BioTelemetry by 13.6% in the fourth quarter. Wells Fargo & Company MN now owns 994,163 shares of the company’s stock valued at $11,612,000 after buying an additional 119,328 shares during the period.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.